Stockreport
Summit Therapeutics' (SMMT) CEO Glyn Edwards on Q4 2017 Results - Earnings Call Transcript [Seeking Alpha]
US:NASDAQ Investor Relations: summitplc.com/investors/investor-centre
PDF
Summit Therapeutics (NASDAQ: SMMT ) Q4 2017 Earnings Conference Call April 11, 2018 8:00 AM ET Executives Richard Pye - Investor Relations Glyn Edwards - Chief Executive Officer David Roblin - Chief Operating Officer and President of Research & Developments Erik Ostrowski - Chief Financial Officer Analysts Arlinda Lee - Canaccord Genuity Tim Chiang - BTIG Debjit Chattopadhyay - H.C. Wainwright Samir Devarni - RX Securities John Gillings - JMP Securities Julie Simmonds - Panmure Gordon Operator Good day. And welcome to the Summit Therapeutics' Conference Call on the Financial Results for the Fourth Quarter and Fiscal Year-ended, 31 January 2018 and Operational Progress. Today's conference is being recorded. At this time, I would like to turn the conference over to Mr. Richard Pye, Senior Director of Corporate Affairs and Communications. Please go ahead, sir. Richard Pye Thank you and welcome to everyone joining us on the call to discuss our
[Read more]
| IMPACT SNAPSHOT | EVENT TIME: | SMMT | ||||
|---|---|---|---|---|---|---|
|
Last Price
|
Price Change
|
Price Change %
|
Volume Shares
|
Max Up
|
Max Down
|
Volume Ratio
%
|
Performance comparison
Updated
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| LAST PRICE | ||
| VWAP | ||
|
High:
|
MAX UP |
High:
|
|
Low:
|
MAX DOWN |
Low:
|
|
%
|
POST NEWS RANGE |
%
|
|
|
PRICE CHANGE |
|
|
|
PRICE CHANGE PERCENTAGE |
|
|
|
S&P 500 (SPX) |
|
|
%
|
VOLUME RATIO |
%
|
| VOLUME (SHARES) | ||
| TICKS | ||
|
|
AVG SHARES PER TRADE |
|
Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Be the first to know
Opt in for alerts from News Quantifed
Opt-in for
SMMT alerts
SMMT alerts
from News Quantified
Movers & Shakers
The biggest gainers and losers and WHY it moved
SMMT alerts
High impacting SUMMIT THERAPEUTICS PLC AMERICA news events
Weekly update
A roundup of the hottest topics
SMMT
NEWS
NEWS
- Summit Awarded up to $4.5 Million Grant from CARB-X for Development of New Mechanism Gonorrhoea Antibiotics[GlobeNewswire]
- SUMMIT THERAPEU/S (NASDAQ: SMMT) was given a new $3.00 price target on by analysts at Canaccord Genuity. They now have a "buy" rating on the stock.[MarketBeat]
- Summit Tumbles 80% On Phase 2 DMD Failure, But The Stock Is Still Worth A Look [Seeking Alpha][Seeking Alpha]
- SUMMIT THERAPEU/S (NASDAQ: SMMT) had its price target lowered by analysts at HC Wainwright to $3.00. They now have a "buy" rating on the stock.[MarketBeat]
- SUMMIT THERAPEU/S (NASDAQ: SMMT) was downgraded by analysts at Janney Montgomery Scott from a "buy" rating to a "neutral" rating.[MarketBeat]
- More
SMMT
SEC Filings
SEC Filings
- 7/17/18 - Form 6-K
- 7/16/18 - Form 6-K
- 7/10/18 - Form 6-K
- SMMT's page on the SEC website
- More